Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?

In brief, I would not.

Here is the evidence I have that leads to this conclusion: The activity of targeted therapy for Ph-like ALL has not been established. There are a number of ongoing studies that are attempting to address this (e.g., AALL1521/INCB18424-269; see Tasian et al., ASH 2022). What data do exist are largely case series and retrospective analyses that are potentially subject to substantial selection bias. Nevertheless, there appears to be more sensitivity of leukemias harboring ABL c...